Browsing: drug

age1 leads Series C as Loyal advances LOY-002 toward FDA approval, completing key requirements for conditional approval. Loyal, the clinical-stage…

Amyloid plaques are misfolded proteins aggregates between neurons, Alzheimer’s disease illustration. [Artur Plawgo/Getty Images] Scientists have long known Alzheimer’s disease…

A research team co-led by scientists at The Wistar Institute has combined a promising cancer therapy with a molecule that…

Phase 1 dosing milestone for MEN2501 signals growing confidence in generative AI drug discovery and its healthspan implications. There is…

Once-a-month shot delivers meaningful weight loss, but Wall Street remains uneasy about competition, tolerability and timing. Pfizer’s obesity moment finally…

Time-resolved fluorescence resonance energy transfer (TR-FRET) combines fluorescence detection with temporal resolution to significantly enhance assay performance. This technology minimizes…

This webinar will be hosted live and available on-demandWednesday, April 8, 202611:00 AM – 3:30 PM ETNew approach methodologies (NAMs)…

Biosplice submits NDA for lorecivivint, a potential first-of-its-kind therapy that aims to slow knee osteoarthritis itself. Osteoarthritis shapes how millions…

Loyal’s lead drug for senior dogs moves closer to market, marking a rare regulatory milestone for lifespan extension. The gray…

Credit: BlackJack3D/Getty Images In November 2024, Boltz-1 debuted as a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the…